Angle Share Discussion Threads

[bagpuss67] 30/1/2024 06:42

Personally I think there is a big risk that Solaris have cooled on AGL who have hardly been dynamic with their Prostate trials. Presently the date when the samples in storage on this will be run is unknown but simply said to be later in 2024.

[broom23] 30/1/2024 00:43

Pasted from wrong thread :

Bones699. You seem hell bent on seeing this share price fall. What is your agenda here?

When the Parsortix was cleared by FDA in May 2022, the share price opened on 98p and closed on 156p, with 11M Angle shares traded. Granted, there was a placing in July of that year, to acquire more funds but this just amounted to a 10% dilution of stock. The sentiment was out there for this stock to be valued at those sort of levels - well north of £1. The company has had some issues but what company has not in these last 3 years. Baillie Gifford took fright - no surprise there - but their stock at each turn was eagerly taken up by Global Frontier - whom still retain it and added to it. The senior management has been strengthened with notable figures.

The market in Breast cancer oncology testing is circa $4B pa, in USA alone. It is double that for Prostate cancer, which is largely due to the very high cost of tissue biopsy. Angle are very keen to enter this market with harvested samples for a partnered liquid assay. They have the only FDA cleared harvester of intact living, blood circulating, cancer cells.

A clinical study (n=100) was set up with MidLantic, affiliated to Solaris in USA, to evaluate the Parsortix use in Prostate cancer patients. The results were expected in 2023. The outcome is as yet unknown - by me - but the intention was for a further study to validate use and make submission to FDA for an extension to the application of the cleared device.

I have no crystal ball but I feel Angle are positioning themselves for a very significant announcement on the Prostate cancer front, with hopefully, good clinical data to back it up. It could be timed to coincide just prior to the Annual Liquid Assay for Precision Oncology at the end of Feb in San Diego this year. If all good, the spike we saw earlier this year will seem paltry.

[dave4545] 29/1/2024 22:55

"Globally, breast cancer is the most frequently diagnosed cancer with 2.3 million new cases per year. In the United States, there are an estimated 3.7 million women living with or after breast cancer and a further 290,000 cases are predicted in 2022. Globally the incidence of breast cancer is growing with cases expected to increase by 80% between 2020 and 2040. Despite new treatment options and advances in patient management protocols, an estimated 30% of women initially diagnosed with earlier stages of breast cancer eventually develop recurrent advanced or metastatic disease. Although the prognosis of patients with metastatic breast cancer has significantly improved over the last two decades, it remains largely incurable with a five-year survival rate of just 29%. ANGLE estimates that the addressable market for the Parsortix system used with metastatic breast cancer patients is in excess of US$500m per annum in the United States alone"

knock yourself out

[bones699] 29/1/2024 21:56

One day you lot will cotton on without FDA approval of the Parsortix machine AGL are going nowhere and a cash raise is inevitable!

[bones699] 29/1/2024 21:53

Unfortunately Parsortix is not FDA approved for testing on over 80% of cancers and thats its ancilles heel...no FDA approval means no sales means no revenues!

[bermudashorts] 29/1/2024 21:05

Sorry no I haven't. Not sure of the rules regarding registration of studies involving analysis of samples of tissue/CTCs/ctDNA etc. I've noticed they don't always appear on clinicaltrials.gov or the European clinical trials register.

[mrkeysersoze] 29/1/2024 20:40

Thanks Bermuda for the reply.... Any idea where the ANG-012 Domino study is lodged?Mr K.

[gooosed] 29/1/2024 20:18

Info on ANG-012 Prostate trial from 26:30

[broom23] 29/1/2024 20:14

Sorry Bermuda, I did not see your post before posting mine- interesting info thanks

[gooosed] 29/1/2024 20:14

Bermudashorts - no worries.....thanks for clarification

[bermudashorts] 29/1/2024 20:11

gooosed - sorry posts crossed

[bermudashorts] 29/1/2024 20:10

MrK,

No it's not the same trial. The Domino prostate study has completed recruitment of 100 patients and the samples are either undergoing or awaiting molecular analysis. The trial on clinicaltrials.gov is an additional study that researchers at Solaris were interested in running in a different area and more limited patient population, but as you say was terminated as they didn't recruit enough patients. It's not related to the main prostate Domino trial.

[gooosed] 29/1/2024 20:08

MrKeysersoze - the trial in your link is entitled as follows :

"Official Title
ANG-015 / MLU-3 (CHARTER Study): Characterization of Circulating Tumor Cells Isolated Using the Parsortix® System in High Risk and Early Metastatic Prostate Cancer Patients"

The Title as described in a slide of last years IMC presentation is entitled ANG-012 as mentioned by Newland at 26:30

He goes on to explain development pathway if successful from there.

[broom23] 29/1/2024 20:08

Mr Keystone. Thanks for this. Posted Sep last year and almost certainly the same study. I am not aware of any post from Angle in the UK - if there ever was one. I feel sure we will hear something soon about their proposals.

[mrkeysersoze] 29/1/2024 18:59

Apologies posted on the wrong BBInteresting new Trial that doesn't appear to have been announced to date, showing on link belowhttps://clinicaltrials.gov/study/NCT05437679?term=Parsortix&viewType=Card&rank=2Anyone have anything further on the link below which appears to show Termination of Prostate Trial, is this the Solaris Trial ? On the face of it, looks like slow / low patient take up.... Initiated the termination.https://clinicaltrials.gov/study/NCT05437679?term=Parsortix&viewType=Card&rank=2Mr K.

[mrkeysersoze] 29/1/2024 18:52

Interesting new Trial that doesn't appear to have been announced to date, showing on link belowhttps://clinicaltrials.gov/study/NCT05437679?term=Parsortix&viewType=Card&rank=2Anyone have anything further on the link below which appears to show Termination of Prostate Trial, is this the Solaris Trial ? On the face of it, looks like slow / low patient take up.... Initiated the termination.https://clinicaltrials.gov/study/NCT05437679?term=Parsortix&viewType=Card&rank=2Mr K.

[gooosed] 29/1/2024 18:43

Broom23 - good post but I suspect (without reading his/her post, as on filter) it's lost on them.

In addition, since Angle signed up with Solaris/MidLantic Solaris has grown from 725,000 to 900,000 patients/annum. So as you say a sizeable opportunity for Angle. It's perhaps worth mentioning that Angle confirmed (as I understand it) that Solaris will be advocating the test on a private pay basis until completion of the larger trial - assuming of course that the initial trial is a success. ⏰

[broom23] 29/1/2024 18:20

Bones699. You seem hell bent on seeing this share price fall. What is your agenda here?

When the Parsortix was cleared by FDA in May 2022, the share price opened on 98p and closed on 156p, with 11M Angle shares traded. Granted, there was a placing in July of that year, to acquire more funds but this just amounted to a 10% dilution of stock. The sentiment was out there for this stock to be valued at those sort of levels - well north of £1. The company has had some issues but what company has not in these last 3 years. Baillie Gifford took fright - no surprise there - but their stock at each turn was eagerly taken up by Global Frontier - whom still retain it and added to it. The senior management has been strengthened with notable figures.

The market in Breast cancer oncology testing is circa $4B pa, in USA alone. It is double that for Prostate cancer, which is largely due to the very high cost of tissue biopsy. Angle are very keen to enter this market with harvested samples for a partnered liquid assay. They have the only FDA cleared harvester of intact living, blood circulating, cancer cells.

A clinical study (n=100) was set up with MidLantic, affiliated to Solaris in USA, to evaluate the Parsortix use in Prostate cancer patients. The results were expected in 2023. The outcome is as yet unknown - by me - but the intention was for a further study to validate use and make submission to FDA for an extension to the application of the cleared device.

I have no crystal ball but I feel Angle are positioning themselves for a very significant announcement on the Prostate cancer front, with hopefully, good clinical data to back it up. It could be timed to coincide just prior to the Annual Liquid Assay for Precision Oncology at the end of Feb in San Diego this year. If all good, the spike we saw earlier this year will seem paltry.

[bagpuss67] 29/1/2024 17:59

Dave. We have had a "seller" on here for ages. The register is a bit thin now on IIs.

[pj84] 29/1/2024 17:34

Sawney I have bones and his nemisis both filtered but which is the moderated thread you refer to? If it's the Dave4545 thread then they are also on my filter list and reluctant to unfilter just to see what is posted there.